Brainstorm Cell (BCLI) director receives 120,000-share RSU award

Rhea-AI Filing Summary

ARBEL IRIT reported acquisition or exercise transactions in this Form 4 filing.

Brainstorm Cell Therapeutics director Irit Arbel received an equity award of 120,000 shares of Common Stock in the form of restricted stock units. The grant was made on February 26, 2026 at a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.

The RSUs were awarded under the company’s 2014 Global Share Option Plan. According to the terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six‑month anniversary of the grant date, as long as Arbel remains employed by the company through each vesting date. After this award, Arbel’s reported direct holdings total 161,054 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ARBEL IRIT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	120,000	$0.00	--

Holdings After Transaction: Common Stock — 161,054 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU award size: 120,000 shares Grant price: $0.00 per share Post-transaction holdings: 161,054 shares +2 more

5 metrics

RSU award size 120,000 shares Restricted stock units granted on February 26, 2026

Grant price $0.00 per share Compensation award, not open-market purchase

Post-transaction holdings 161,054 shares Total Common Stock held directly after the award

Initial vesting portion 50% of award Vests on the RSU grant date

Deferred vesting portion 50% of award Vests six months after grant if employment continues

Key Terms

restricted stock units ("RSUs"), 2014 Global Share Option Plan, vesting date

3 terms

restricted stock units ("RSUs") financial

"Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2014 Global Share Option Plan financial

"RSUs awarded under the 2014 Global Share Option Plan."

vesting date financial

"provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARBEL IRIT

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		120,000(1)	A	$0.00	161,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Irit Arbel	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BCLI director Irit Arbel acquire in this Form 4 filing?

Irit Arbel received an equity award of 120,000 restricted stock units representing Common Stock of Brainstorm Cell Therapeutics. The grant is compensation at a stated price of $0.00 per share under the company’s 2014 Global Share Option Plan.

How do the 120,000 RSUs granted to BCLI director Irit Arbel vest?

The 120,000 RSUs vest in two equal tranches. Half of the award vests on the grant date, and the remaining half vests on the six‑month anniversary, provided Arbel remains employed by Brainstorm Cell Therapeutics through each vesting date.

What are Irit Arbel’s total reported BCLI holdings after this RSU grant?

Following the RSU award, Irit Arbel is reported as holding 161,054 shares of Brainstorm Cell Therapeutics Common Stock directly. This figure reflects the position after the 120,000-share restricted stock unit award disclosed in the Form 4.

Was cash paid for the 120,000 BCLI shares reported in this Form 4?

No cash was paid; the Form 4 reports a transaction price of $0.00 per share. The 120,000 shares were granted as restricted stock units under Brainstorm Cell Therapeutics’ 2014 Global Share Option Plan as part of compensation.

What employment condition is tied to Irit Arbel’s BCLI RSU grant?

The remaining 50% of the RSU award vests only if Irit Arbel continues employment with Brainstorm Cell Therapeutics through the six‑month anniversary of the grant date, as specified in the award’s vesting terms.